activin A receptor like type 1
Last updated 20 May 2021
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The ACVRL1 gene provides instructions for making a protein called activin receptor-like kinase 1. This protein is found on the surface of cells, especially in the lining of developing arteries.
Video picks for GenesVideo library
Normal function
The ACVRL1 gene provides instructions for making a protein called activin receptor-like kinase 1. This protein is found on the surface of cells, especially in the lining of developing arteries.
The ACVRL1 protein is a receptor. It acts as a "lock" waiting for a specific protein, called its ligand, to serve as the "key." In the case of the ACVRL1 protein, the ligand is called transforming growth factor beta. The interaction between these proteins plays a role in the development of blood vessels. In particular, this protein interaction is involved in the specialization of new blood vessels into arteries or veins.
Conditions referring to this gene or chromosome
Other names
activin A receptor type II-like 1
activin A receptor type IL
Activin A receptor, type II-like kinase 1
ACVL1_HUMAN
ACVRLK1
ALK-1
ALK1
EC 2.7.1.37
HHT
HHT2
ORW2
Serine/threonine-protein kinase Receptor R3 Precursor
SKR3
TGF-B Superfamily Receptor Type I
Patient picks for Genes

Diabetes
MHRA approves teplizumab to delay progression of type 1 diabetes
Teplizumab (Tzield) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help delay the onset of Stage 3 type 1 diabetes (T1D). Read on to see what this means if you are prescribed teplizumab and what it does for you.
by Lawrence Higgins

Diabetes
Slowdown in type 2 diabetes cases
Some countries have seen a fall in new cases of type 2 diabetes according to a new review of the current evidence.
by Milly Evans

Diabetes
Signs of type 2 diabetes found in children as young as eight
The early signs of type 2 diabetes are visible in children as young as eight years old, according to new research.
by Milly Evans

Diabetes
Can diet drinks cause type 2 diabetes?
We're all used to the headlines about the 'global epidemic' of type 2 diabetes. We should all know that completely unlike type 1 diabetes, getting type 2 diabetes is largely about lifestyle.
by Dr Sarah Jarvis

Diabetes
Continuous glucose monitoring in type 1 diabetes
Type 1 and type 2 diabetes are both potentially serious conditions which should always be taken seriously. They’re both diagnosed on the basis of high blood sugar. But in other respects they are very, very different. Type 2 is largely down to lifestyle – getting type 1 is absolutely nothing to do with whether you eat too much sugar, carry excess weight or don’t exercise enough. People with type 2 diabetes often never need insulin – those with type 1 need it from day one. Many people with type 2 diabetes never need treatment that carries a risk of disabling low blood sugar (hypoglycaemia) – people with type 1 live with this risk every day. As a result, many people with type 2 never need to check their blood sugar several times a day – for people with type 1, it’s a highly unwelcome occupational hazard.
by Dr Sarah Jarvis

Diabetes
Changes in type 2 diabetes care - what it means for you
If you are living with type 2 diabetes your treatment may soon change to be tailored around you and your specific needs - which will help improve your long-term health. Read on to find out what the changes are and what they mean for you.
by Lawrence Higgins
Related patient information and medicines

Patient information leaflet
Immunisation for flu
Getting the flu vaccine is a safe and effective way to protect against becoming seriously ill with flu. What is the flu jab for. Influenza (flu) Flu is a common viral infection that tends to be most common in the winter. Flu can cause much more severe symptoms than the common cold Common cold. Some people can become seriously ill with flu, needing.

Patient information leaflet
Nausea medicine
Various medicines are available to treat nausea. Listed below are some of the more commonly prescribed medicines: Cinnarizine Cinnarizine tablets , cyclizine Cyclizine for sickness , promethazine Promethazine - these medicines belong to a group of medicines called antihistamines Antihistamines. Aprepitant Aprepitant to prevent sickness and.

Patient information leaflet
Myasthenia gravis
Myasthenia gravis (MG) is a condition where muscles become easily tired and weak. What causes myasthenia gravis. Myasthenia gravis is an autoimmune disease. This means that the immune system The immune system (which normally protects the body from infections) mistakenly attacks itself. (Other autoimmune diseases include type 1 diabetes Type 1.

Patient information leaflet
Can I take Alogliptin and Rybelsus together?
Taking alogliptin and Rybelsus (semaglutide) together can significantly increase the risk of your blood sugar dropping too low (hypoglycaemia). Alogliptin (a DPP-4 inhibitor) prevents the breakdown of natural hormones that lower blood sugar, while Rybelsus (a GLP-1 receptor agonist) mimics those same hormones. Using both is like 'doubling up' on.

Patient information leaflet
Insulin
Insulin is a hormone made naturally in the body by the pancreas. For more information on insulin, go to [https://patient.info/health/type-1-diabetes/insulins](https://patient.info/health/type-1-diabetes/insulins) Insulin is a hormone that is made by cells called beta cells. There are two different types of diabetes: Type 1 diabetes Type 1 diabetes.

Patient information leaflet
Type 2 diabetes
Type 2 diabetes can occur at any age, including during childhood, but it occurs mainly in people aged over 40. This is because in type 2 diabetes you still make insulin (unlike in type 1 diabetes Type 1 diabetes ). ... Many people have diabetes for a long period of time before their diagnosis is made..
Further reading and references
- activin A receptor like type 1; MedlinePlus, National Library of Medicine.
- Azuma H. Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J Med Invest. 2000 Aug;47(3-4):81-90.
- Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005 Feb 15;65(3):599-608. doi: 10.1016/j.cardiores.2004.10.036.
- Lesca G, Plauchu H, Coulet F, Lefebvre S, Plessis G, Odent S, Riviere S, Leheup B, Goizet C, Carette MF, Cordier JF, Pinson S, Soubrier F, Calender A, Giraud S; French Rendu-Osler Network. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat. 2004 Apr;23(4):289-99. doi: 10.1002/humu.20017.
- Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, Lindhout D, Hennekam FA, Westermann CJ, Ploos van Amstel JK. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet. 2005 Jan;116(1-2):8-16. doi: 10.1007/s00439-004-1196-5. Epub 2004 Oct 23.
- Pawlikowska L, Tran MN, Achrol AS, Ha C, Burchard E, Choudhry S, Zaroff J, Lawton MT, Castro R, McCulloch CE, Marchuk D, Kwok PY, Young WL; UCSF BAVM Study Project. Polymorphisms in transforming growth factor-beta-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke. 2005 Oct;36(10):2278-80. doi: 10.1161/01.STR.0000182253.91167.fa. Epub 2005 Sep 22.
- van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res. 2003 Apr 1;58(1):20-31. doi: 10.1016/s0008-6363(02)00852-0.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

